Wavefront-optimized treatment for myopia using Allegretto Wave Eye-Q excimer laser
Celeste P. Guzman, MD, Jessica Marie R. Abano, MD
To evaluate the efficacy, predictability, and safety of LASIK surgery using the Allegretto Wave Eye-Q excimer laser.
Data of patients who underwent myopic LASIK were collected. The data consisted of pre- and postoperative refractions, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), and intraoperative treatment parameters. The main outcome measures were efficacy, predictability, and safety.
One hundred eight eyes of 56 patients, 21 males and 35 females, mean age of 30.66 years, who underwent myopic LASIK in a tertiary hospital, were included in the study. The mean spherical error corrected was –5.22 ±2.56 D (median, –5.0 D). Postoperatively, all eyes achieved UCVA of 20/30 or better, with 92.6% achieving 20/20. Nearly 94% of patients maintained or gained 1 to 2 Snellen lines of BCVA postoperatively. One patient lost 2 Snellen line of BCVA. The mean postoperative manifest refraction spherical equivalent (MRSE) was –0.04 ± 0.26 D. The general refractive predictability was 93.52% within ± 0.5 D from the target refraction, while 76% of all patients had a postoperative MRSE of within ± 0.25 of the target.
Myopic LASIK performed using the Allegretto Wave Eye-Q excimer laser is safe and effective with high refractive predictability.
Keywords: Myopia, LASIK, Excimer laser, Visual Acuity, Wavefront